Skip to main content

Month: September 2025

Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio

SARASOTA, FL, Sept. 03, 2025 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that IP Australia (the Australian Patent Office) has granted patent number 2020271839 to Silo’s research and licensing partner Columbia University for the invention titled “Prophylactic efficacy of serotonin 4 receptor agonists against stress” exclusively licensed to Silo by Columbia University. The patent reinforces protection for Silo’s lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD), originally developed by Columbia University. “This patent further strengthens our global IP portfolio for SPC-15, protecting its novel approach to preventing stress-induced disorders and enhancing...

Continue reading

Sodexo and EAT Announce Strategic Partnership to Promote Healthy and Sustainable Eating

Paris – September 3, 2025   Sodexo and EAT are pleased to announce a new partnership to advance healthier and more sustainable eating habits. As EAT’s exclusive partner from the food service industry, Sodexo is proud to bring its global expertise to translate cutting-edge science into practical, scalable solutions that make food choices good for the people and the planet accessible to all. The partnership is rooted in a shared commitment to promote and inspire healthier and more sustainable eating. It will be highlighted for the first time at the Stockholm Food Forum, taking place in Stockholm on October 3-4, 2025. For Sodexo, which serves more than 80 million consumers daily, partnering with EAT, a leading player in food system transformation, is a critical asset to encourage and accelerate the adoption of better food habits. For...

Continue reading

CG Oncology Completes Enrollment in PIVOT-006

– Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) –– One of the largest randomized phase 3 studies in this patient population will encompass broadest range of patient types per AUA/SUO Guidelines – IRVINE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that it has completed enrollment in its Phase 3, randomized, open-label PIVOT-006 study comparing adjuvant intravesical cretostimogene grenadenorepvec versus surveillance following bladder tumor removal in patients with intermediate-risk non-muscle invasive bladder cancer (IR NMIBC). “Intermediate-risk NMIBC...

Continue reading

MIMEDX to Sponsor and Attend Symposium on Advanced Wound Care (SAWC) Fall

To Present Six Posters Featuring the Company’s Latest Product Innovations MARIETTA, Ga., Sept. 03, 2025 (GLOBE NEWSWIRE) — MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced its schedule for the Symposium on Advanced Wound Care (SAWC) Fall meeting taking place September 3-6 in Las Vegas, NV. SAWC remains a premier event for clinicians and industry professionals to explore the latest clinical evidence and innovations in advanced wound care. The Company will showcase its leading advanced wound care portfolio in the exhibit hall at booth 511. Sponsored Lunch SymposiumTitle: Change is Inevitable: Mastering the Art of Wound Healing in an Evolving LandscapeDate: Thursday, September 4, 2025Time: 11:40 – 1:10 p.m. PDTFaculty: Paul Kim, DPM, MS, FACFAS; Nicolas Mouawad, MD, MPH, MBA, DFSVS, FRCS, FACS, RPVI; Scott...

Continue reading

Verkkokauppa.com Oyj strengthens its management team and appoints a new Chief Supply Chain Officer

Verkkokauppa.com Oyj strengthens its management team and appoints a new Chief Supply Chain Officer  Verkkokauppa.com Oyj STOCK EXCHANGE RELEASE 3 September 2025 at 03:00 p.m. EESTAnne-Mari Paapio (MSc) has been appointed Chief Supply Chain Officer of Verkkokauppa.com. She most recently served as Vice President of Procurement and Category Management at Valio Aimo, where she drove strategic initiatives in sourcing and category development. Prior to that, she led consulting projects as a Project Leader at Boston Consulting Group. She has strong strategic supply chain management expertise and a solid background in customer-centric operations within retail. Anne-Mari will report to the CEO and become a member of the management team. She will start in the new position on 10 September 2025.   CEO Panu Porkka: “I am pleased to welcome...

Continue reading

Glass House Brands Announces the Passing of Board Member George Raveling

LONG BEACH, Calif. and TORONTO, Sept. 03, 2025 (GLOBE NEWSWIRE) — Glass House Brands Inc. (“Glass House” or the “Company”) (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF), one of the fastest-growing, vertically-integrated cannabis companies in the U.S., today announced with great sadness the passing of Mr. George Raveling, a valued member of the Company’s Board of Directors and the Glass House family. Mr. Raveling joined the Board in 2021 when the company went public, bringing with him extensive experience in marketing and corporate governance. As an inductee of the Naismith Basketball Hall of Fame and the College Basketball Hall of Fame for his coaching career accomplishments and having been Nike’s Director of International Basketball, Mr. Raveling brought immeasurable leadership to...

Continue reading

NuCana to Present Data on NUC-7738’s Synergy with PD-1 Inhibitors at the ESMO Congress 2025

EDINBURGH, United Kingdom, Sept. 03, 2025 (GLOBE NEWSWIRE) — NuCana plc (Nasdaq: NCNA) (“NuCana” or the “Company”) announced a presentation at the upcoming annual European Society for Medical Oncology (“ESMO”) congress being held October 17-21, 2025 in Berlin, Germany (the “ESMO Congress 2025”). The details of NuCana’s presentation at the meeting are as follows: Abstract Title: Patient Derived Organoids Reveal Synergy Between NUC-7738 and PD-1 Inhibition in Renal Cell Cancer Poster Number: 1530PSession: Investigational ImmunotherapyDate: Sunday, October 19, 2025Presenting Author: H. Abdullah All regular abstracts accepted for presentation at the ESMO Congress 2025 will be published online via the ESMO website on Monday, October 13 at 6:05 p.m. ET (12:05 a.m. CEST). All accepted abstracts will be published online in the ESMO Congress...

Continue reading

Becklar Adds Dynamark Monitoring to Its Expanding Portfolio of Monitoring Centers

Ogden, Utah, Sept. 03, 2025 (GLOBE NEWSWIRE) — Becklar, the SMART Critical Event Monitoring Company, is pleased to announce the acquisition of Dynamark Monitoring, a leading provider of wholesale monitoring services in the U.S.   Dynamark has earned a healthy presence and reputation in the security industry for over 50 years. They opened their first UL-listed monitoring center in 2010 in Hagerstown, MD, officially launching Dynamark Monitoring. Since then, they have grown into a leader in critical event monitoring. Their growth included the acquisition of a regional monitoring center, followed by the addition of a second monitoring station in Corona, CA, in 2024. Trey Alter founded Dynamark to provide alarm dealers with cutting-edge technology and with support from people who genuinely care about the success of their dealer partners,...

Continue reading

MachTen Reports Financial Results for the Second Quarter of 2025

TRAVERSE CITY, Mich., Sept. 03, 2025 (GLOBE NEWSWIRE) — MachTen, Inc. (OTC: MACT) today announced financial results for the second quarter and six months ended June 30, 2025. “We continue to execute our fiber-based investment plan, while improving the operational foundation for sustained growth,” said Dan Miller, Chief Executive Officer. “Our team remains focused on establishing the most reliable broadband network in the communities we serve and driving long-term value for customers and shareholders.”Second Quarter 2025 Financial HighlightsRevenue: $4.22 million vs $4.25 million in 2Q24, as subscriber gains in our fiber-optic footprint were offset by declines in voice services provided on the legacy copper network. New orders for fiber internet in July and August exceed 350 customers, with additional pre-orders of more than...

Continue reading

United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Kidney Test for Home Use

10-minute home test detects early kidney damage in diabetic and hypertensive patients Hypertension affects roughly one-third of adults in the UAE Diabetes impacts approximately one in four UAE nationalsIRVINE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) — Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, announced today announced that the United Arab Emirates (UAE) Ministry of Health and Prevention has approved its Fortel® Kidney Test for home use. This important regulatory milestone expands access to accurate, easy-to-use diagnostic tools supporting early identification of kidney damage in high-risk populations. The Fortel® Kidney Test is a rapid, 10-minute easy to use diagnostic test that detects low levels of albumin in urine, a critical early marker of kidney disease. The test is particularly...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.